CHEK1 and ovarian carcinoma: Inhibition of HMGB3 in cisplatin-resistant ovarian cancer cells resulted in transcriptional downregulation of ATR and CHK1, subsequently attenuating the ATR/CHK1/p-CHK1 DNA damage signalling pathway [19].